Atherosclerotic cardiovascular (CV) disease (ASCVD) incidence and mortality rates are
declining in many countries in Europe, but it is still a major cause of morbidity and mortality …

Off-label use of medication may be presented in these guidelines if a sufficient level of
evidence shows that it can be considered medically appropriate to a given condition and if …

Health professionals are encouraged to take the Guidelines fully into account when
exercising their clinical judgment, as well as in the determination and the implementation of …

Each section has been revised or rewritten and five new sections added:(i) management of
free floating thrombus (section 4.13),(ii) management of carotid webs (section 4.14),(iii) …

• The specific situation of the patient. Unless otherwise provided for by national regulations,
off-label use of medication should be limited to situations where it is in the patient's interest …

• The specific situation of the patient. Unless otherwise provided for by national regulations,
off-label use of medication should be limited to situations where it is in the patient's interest …

Cardiovascular disease remains the leading cause of death in patients with diabetes.
Cardiovascular disease in diabetes is multifactorial, and control of the cardiovascular risk …

Guideline Summary Chronic limb-threatening ischemia (CLTI) is associated with mortality,
amputation, and impaired quality of life. These Global Vascular Guidelines (GVG) are …

Importance Acute coronary syndromes (ACS) are characterized by a sudden reduction in
blood supply to the heart and include ST-segment elevation myocardial infarction (STEMI) …

Atherosclerotic lower extremity peripheral artery disease (PAD) is increasingly recognized
as an important cause of cardiovascular morbidity and mortality that affects> 230 million …